Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,196 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04978012 | Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy | unknown | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT05403333 | Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer | unknown | Phase 2 | 61 | Fudan UniversityOTHER | 0 | Jun 3, 2022 | clinicaltrials |
| NCT05018702 |
| ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases |
| unknown |
| Phase 2 |
| 32 |
| Fudan UniversityOTHER |
| 1 |
| Jun 1, 2022 |
| clinicaltrials |
| NCT05396937 | Efficacy and Safety of T+A+RAD in HCC | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT04992156 | Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET | completed | — | 50 | Fudan UniversityOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05371301 | Efficacy of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer | unknown | Phase 3 | 200 | Fudan UniversityOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT05350891 | Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC | unknown | Phase 2 | 77 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT05354076 | Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05346328 | HER2-positive Breast Cancer Project Initiated by Investigators | unknown | Phase 2 | 48 | Fudan UniversityOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT05346861 | Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab | unknown | Phase 3 | 240 | Fudan UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05018676 | ARX788 in Breast Cancer With Low Expression of HER2 | unknown | Phase 2 | 54 | Fudan UniversityOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT02546934 | ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)(TNBC) | completed | Phase 3 | 254 | Fudan UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT05341479 | An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma | unknown | — | 200 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT02336750 | Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis | completed | Phase 3 | 212 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT02341911 | Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)(TNBC) | unknown | Phase 2 | 150 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT02607215 | Platinum Rechallenge in Patients With Platinum-sensitive mTNBC | unknown | Phase 2 | 84 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT02909361 | Fulvestrant 500mg in Patients With Advanced Breast Cancer | unknown | — | 500 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03071926 | Metronomic PLD in Patients With Primary Endocrine Resistant ABC | unknown | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03251313 | PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients | unknown | Phase 1 | 31 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03254654 | Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer | completed | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04192903 | Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer | unknown | Phase 2 | 55 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04745975 | Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer | unknown | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04758416 | Study on the Value of Non-invasive Dual-Pet Information in Subtype of Metastatic Breast Cancer | unknown | — | 50 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04769050 | Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment | unknown | — | 50 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04848597 | PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP | unknown | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05316480 | Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms | not yet recruiting | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05311319 | HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT04508816 | Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | completed | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04508829 | Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 52 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04921995 | Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma(RETICULA-NPC) | unknown | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05019677 | GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC | withdrawn | Phase 2 | 0 | Fudan UniversityOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT02817126 | Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer(REAL) | unknown | N/A | 1,240 | Fudan UniversityOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05290337 | ZR-CHOP in DLBCL With Specific Gene Abnormality | unknown | Phase 2 | 62 | Fudan UniversityOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05212857 | Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer | unknown | Phase 2 | 160 | Fudan UniversityOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT05201430 | Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer(RCNAC) | recruiting | Phase 3 | 300 | Fudan UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05265793 | Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05142631 | Fruquintinib in the Treatment of Soft Tissue Sarcoma | unknown | Phase 2 | 31 | Fudan UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05257122 | A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05238064 | Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL | unknown | Phase 1 / Phase 2 | 30 | Fudan UniversityOTHER | 0 | Feb 14, 2022 | clinicaltrials |
| NCT02459457 | A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer | completed | Phase 3 | 321 | Fudan UniversityOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT04617821 | AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer | unknown | Phase 3 | 300 | Fudan UniversityOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT03737591 | The Implication of Plasma ctDNA Methylation Haplotypes in Detecting Colorectal Cancer and Adenomas | completed | — | 1,138 | Fudan UniversityOTHER | 1 | Jan 25, 2022 | clinicaltrials |
| NCT03278600 | Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary | completed | Phase 3 | 182 | Fudan UniversityOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT04995120 | Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma(INSIGHT) | unknown | Phase 2 | 42 | Fudan UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT05168527 | The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05191849 | Circulating EV Long RNA Profiles in SCLC | unknown | N/A | 60 | Fudan UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05193292 | Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer | unknown | Phase 2 | 77 | Fudan UniversityOTHER | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05188911 | Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial | unknown | — | 30 | Fudan UniversityOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT05164510 | Value of ctDNA in the Treatment of Multiple Primary Cancers | unknown | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Dec 20, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials